We are committed to serving the best interests of our shareholders.

Filter Releases
 
Press Releases
Date Title and Summary View
6/07/2017 WALTHAM, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation at the Goldman Sachs 38th Annual Global Healthcare Conference, to be held June 13-15, 2017 at the Terranea Resort in Rancho Palos Verdes, California. Tim Pearson, ...
6/03/2017 Initial TOPACIO data for niraparib plus KEYTRUDA® is indicative of potentially synergistic anti-tumor activity in platinum-resistant ovarian cancerPhase 1 results for TSR-042 show anti-PD-1 activityThree posters presented during ASCO describe additional an...
5/25/2017 Investor briefing to be webcast from Chicago on June 3, 2017 at 6:15 PM CT WALTHAM, Mass., May 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of three ZEJULA™ (niraparib) abstracts at...
5/22/2017 WALTHAM, Mass., May 22, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the results of the ...
5/11/2017 WALTHAM, Mass., May 11, 2017 (GLOBE NEWSWIRE) -- TESARO Inc. (NASDAQ:TSRO) and Clinigen Group plc's (AIM:CLIN) ('Clinigen') Idis Managed Access division have partnered to launch a Managed Access Program (also known as an Early Access Program) in Europe for the investigational PARP 1/2 inhibitor, niraparib, for patients with r...
5/09/2017 ZEJULA™ approved by U.S. FDA for the maintenance treatment of women with recurrent ovarian cancer, regardless of BRCA or biomarker status; commercial launch underwayZEJULA added to the NCCN Clinical Practice Guidelines in Oncology Expanded development program for niraparib ...
5/01/2017 WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND) Application for TSR-033 to the U.S. Food and Drug Administration. TSR-033 is a monoclonal antibody targeting LAG-3."The IND ...
4/27/2017 TSR-042 is the first TESARO immuno-oncology candidate to enter a registration programOngoing clinical trial expanded to enroll patients with endometrial cancerPatient-centric administration schedule with every 6 week dosing...
4/26/2017 VARUBY provides protection for delayed chemotherapy-induced nausea and vomiting (CINV) with a single dose as part of an antiemetic regimenUp to 50% of patients undergoing highly or moderately emetogenic chemotherapy experience delayed CINV even when prescribed a 5-HT3 receptor antagonist ...
4/25/2017 WALTHAM, Mass., April 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:The Leerink Boston Biopharma Bus Tour on Wednesday, May 10, 2017....
Page:
...
Next Last
 
= add release to Briefcase